{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'UAB', 'University of Alabama at Birmingham', 'ULT', 'Urate Lowering Therapy', 'USP', 'United States Pharmacopeia', 'UM', 'University of Michigan', '11.4 PROTOCOL AMENDMENT HISTORY', 'The table below is intended to capture changes of IRB-approved versions of the protocol, including a description of the', 'change and rationale. A Summary of Changes table for the current amendment is located in the Protocol Title Page.', 'Version', 'Date', 'Description of Change', 'Brief Rationale', '2.0', '02/14/2018', 'Updated objects', 'Request of NIAMS/KAI', '3.0', '03/12/2018', 'Updated page numbers', 'Request of NIAMS/KAI', 'Updated section 2 to match section 4', 'Request of NIAMS/KAI to', 'for consistency', 'address inconsistency in text', 'Corrected fasting before infusion', 'Request of NIAMS/KAI to', 'Detailed unblinding process', 'address a discordance in text.', 'Updated abnormal lab values as AEs', 'Request of NIAMS/KAI to', 'Defined Unanticipated AE (UAE)', 'address events that would lead to', 'Updated timing of SAE reporting.', 'unblinding and reporting to', 'Fixed typo', 'NIAMS/KAI/DSMB', 'Clarified definition of population and', 'Request of NIAMS/KAI to revise', 'planned analysis', 'the protocol to include all', 'Updated timing of reporting of', 'abnormal lab values or test results', 'protocol deviations.', 'at AEs', 'Request of NIAMS/KAI to', 'provide definition of UAE', 'Request of NIAMS/KAI to', 'specify that NIAMS and the', 'DSMB via KAI will be updated', 'within 48 hours', 'Request of NIAMS/KAI to', 'correct the typo in section 10.1', 'Request of NIAMS/KAI to', 'identify and further describe the', 'analysis datasets', 'Request of NIAMS/KAI to', 'specify that NIAMS and the', 'DSMB via KAI will be notified', 'within 48 hours of protocol', 'deviations', '4.0', '3/21/2018', 'Added text to specify all SAE', 'Request of KAI/NIAMS', 'regardless of relatedness will be', 'reported to the NIAMS and DSMB via', 'KAI w/in 48 hours', '5.0', '06/19/2018', 'Updated study roster', 'Rachel Burrell, PharmD has', 'moved to part-time status. Add', 'Chris Chapleau as lead UAB', 'pharmacist', '6.0', '07/12/2018', 'Start participants on MMF/placebo', 'To ensure tolerability to MMF', '500mg/twice a day for the first week,', 'and identify potential MMF', 'and if tolerated titrate the dose up to', 'intolerance earlier', '1000mg/twice a day for the second', 'Collection of CBC at run-in is', 'week of run-in prior to the first', 'unnecessary as it will be collected', '43']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'infusion.', 'at screening and before each', 'Removal of CBC collection at run-in', 'infusion visit', 'visit', 'Recommendation from the', 'Collection of banked specimen to', 'DSMB', 'measure adherence to MMF at all', 'By decreasing the number of pills', 'study visits during the dual therapy', 'given to participants, it will', 'phase', 'decrease participant burden due to', 'Supply participants with a two-week', 'high volume of pills and will', 'supply of MMF/placebo and assess', 'increase compliance with study', 'compliance at every infusion visit', 'medication', 'during the dual therapy phase', 'Not usually included on CMP,', 'Addition of HDL/LDL collection time', 'need to specifically ask for lab', 'points', 'values on lab order sheet', 'Addition of gene expression and', 'Tests added to measure the effect', 'epigenetics blood collection time', 'of urate-lowering therapy on the', 'points', 'epigenome and gene expression', '7.0', '07/18/2018', 'Addition of corticosteroids as second-', 'To improve patient quality and', 'tier rescue medication', 'avoid dropouts, corticosteroids', 'will be given if first-line', 'medications (NSAIDS and', 'colchicine) are ineffective', '8.0', '07/19/2018', 'Addition of medical monitors', 'Drs. David Fox and Angelo Gaffo', 'have been added as medical', 'monitors, and will assist/provide', 'site investigators in answering', 'clinical relevant questions', '9.0', '09/13/2018', 'Deletion of LDL and HDL lab', 'Lab values are not necessary', 'collection', 'To gain a better understanding of', 'Addition of sUA check at Visit 4', 'the sUA levels in between', 'infusion 1 and 2.', '10.0', '12/04/2018', 'Revision of follow-up visits post', 'Participants who have', 'participant treatment failure/infusion', 'experienced pegloticase treatment', 'reaction. Will conduct visit 17 (two', 'failure or otherwise discontinue', 'weeks post treatment failure/infusion', 'pegloticase and are off study drug', 'reaction) and visits 18-20 (once a', '(MMF or placebo) require less', 'month for three months)', 'regular safety evaluations. The', 'half-life of MMF and pegloticase', '(the active medications) is about', '17 hours and 10-12 days', 'respectively. Adverse effects,', 'which may be attributable to', 'either drug, are time limited', 'following treatment', 'discontinuation. This revision', 'will limit participant burden and', 'encourage continuation in study.', '11.0', '1/10/2019', 'Addition of a weight restriction of', 'To minimize the likelihood of', '160kg', 'primary pegloticase treatment', 'failures due to weight exceeding', '160kg', '12.0', '1/13/2020', 'Clarified recording of lab results and', 'Request from NIAMS/KAI', 'the process for signing off on labs', 'Request from NIAMS/KAI', 'AE/SAE review', '44']\n\n###\n\n", "completion": "END"}